Emily M Bucholz1, Richard P Whitlock2, Michael Zappitelli3, Prasad Devarajan4, John Eikelboom5, Amit X Garg6, Heather Thiessen Philbrook7, Philip J Devereaux8, Catherine D Krawczeski9, Peter Kavsak10, Colleen Shortt10, Chirag R Parikh11. 1. School of Medicine, and Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, Connecticut; 2. Division of Cardiac Surgery, Population Health Research Institute, and. 3. Division of Nephrology, Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada; 4. Department of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; 5. Division of Cardiac Surgery, Population Health Research Institute, and Medicine, and. 6. Division of Nephrology, Department of Medicine, and Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada; 7. Division of Nephrology, Department of Medicine, and. 8. Departments of Clinical Epidemiology and Biostatistics. 9. Division of Pediatric Cardiology, Lucile Packard Children's Hospital, Stanford University School of Medicine, Palo Alto, California; and. 10. Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada; 11. Department of Internal Medicine, Clinical Epidemiology Research Center, Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut chirag.parikh@yale.edu.
Abstract
OBJECTIVES: To examine the relationship of cardiac biomarkers with postoperative acute kidney injury (AKI) among pediatric patients undergoing cardiac surgery. METHODS: Data from TRIBE-AKI, a prospective study of children undergoing cardiac surgery, were used to examine the association of cardiac biomarkers (N-type pro-B-type natriuretic peptide, creatine kinase-MB [CK-MB], heart-type fatty acid binding protein [h-FABP], and troponins I and T) with the development of postoperative AKI. Cardiac biomarkers were collected before and 0 to 6 hours after surgery. AKI was defined as a ≥ 50% or 0.3 mg/dL increase in serum creatinine, within 7 days of surgery. RESULTS: Of the 106 patients included in this study, 55 (52%) developed AKI after cardiac surgery. Patients who developed AKI had higher median levels of pre- and postoperative cardiac biomarkers compared with patients without AKI (all P < .01). Preoperatively, higher levels of CK-MB and h-FABP were associated with increased odds of developing AKI (CK-MB: adjusted odds ratio 4.58, 95% confidence interval [CI] 1.56-13.41; h-FABP: adjusted odds ratio 2.76, 95% CI 1.27-6.03). When combined with clinical models, both preoperative CK-MB and h-FABP provided good discrimination (area under the curve 0.77, 95% CI 0.68-0.87, and 0.78, 95% CI 0.68-0.87, respectively) and improved reclassification indices. Cardiac biomarkers collected postoperatively did not significantly improve the prediction of AKI beyond clinical models. CONCLUSIONS: Preoperative CK-MB and h-FABP are associated with increased risk of postoperative AKI and provide good discrimination of patients who develop AKI. These biomarkers may be useful for risk stratifying patients undergoing cardiac surgery.
OBJECTIVES: To examine the relationship of cardiac biomarkers with postoperative acute kidney injury (AKI) among pediatric patients undergoing cardiac surgery. METHODS: Data from TRIBE-AKI, a prospective study of children undergoing cardiac surgery, were used to examine the association of cardiac biomarkers (N-type pro-B-type natriuretic peptide, creatine kinase-MB [CK-MB], heart-type fatty acid binding protein [h-FABP], and troponins I and T) with the development of postoperative AKI. Cardiac biomarkers were collected before and 0 to 6 hours after surgery. AKI was defined as a ≥ 50% or 0.3 mg/dL increase in serum creatinine, within 7 days of surgery. RESULTS: Of the 106 patients included in this study, 55 (52%) developed AKI after cardiac surgery. Patients who developed AKI had higher median levels of pre- and postoperative cardiac biomarkers compared with patients without AKI (all P < .01). Preoperatively, higher levels of CK-MB and h-FABP were associated with increased odds of developing AKI (CK-MB: adjusted odds ratio 4.58, 95% confidence interval [CI] 1.56-13.41; h-FABP: adjusted odds ratio 2.76, 95% CI 1.27-6.03). When combined with clinical models, both preoperative CK-MB and h-FABP provided good discrimination (area under the curve 0.77, 95% CI 0.68-0.87, and 0.78, 95% CI 0.68-0.87, respectively) and improved reclassification indices. Cardiac biomarkers collected postoperatively did not significantly improve the prediction of AKI beyond clinical models. CONCLUSIONS: Preoperative CK-MB and h-FABP are associated with increased risk of postoperative AKI and provide good discrimination of patients who develop AKI. These biomarkers may be useful for risk stratifying patients undergoing cardiac surgery.
Authors: Chirag R Parikh; Prasad Devarajan; Michael Zappitelli; Kyaw Sint; Heather Thiessen-Philbrook; Simon Li; Richard W Kim; Jay L Koyner; Steven G Coca; Charles L Edelstein; Michael G Shlipak; Amit X Garg; Catherine D Krawczeski Journal: J Am Soc Nephrol Date: 2011-08-11 Impact factor: 10.121
Authors: Thomas L Nickolas; Kai M Schmidt-Ott; Pietro Canetta; Catherine Forster; Eugenia Singer; Meghan Sise; Antje Elger; Omar Maarouf; David Antonio Sola-Del Valle; Matthew O'Rourke; Evan Sherman; Peter Lee; Abdallah Geara; Philip Imus; Achuta Guddati; Allison Polland; Wasiq Rahman; Saban Elitok; Nasir Malik; James Giglio; Suzanne El-Sayegh; Prasad Devarajan; Sudarshan Hebbar; Subodh J Saggi; Barry Hahn; Ralph Kettritz; Friedrich C Luft; Jonathan Barasch Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Isaac E Hall; Steven G Coca; Mark A Perazella; Umo U Eko; Randy L Luciano; Patricia R Peter; Won K Han; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2011-10-27 Impact factor: 8.237
Authors: Joshua J Blinder; Stuart L Goldstein; Vei-Vei Lee; Alixandra Baycroft; Charles D Fraser; David Nelson; John L Jefferies Journal: J Thorac Cardiovasc Surg Date: 2011-07-27 Impact factor: 5.209
Authors: Yuichiro Z Sato; Delaram P Molkara; Lori B Daniels; Adriana H Tremoulet; Chisato Shimizu; John T Kanegaye; Brookie M Best; James V Snider; Jeffrey R Frazer; Alan Maisel; Jane C Burns Journal: Int J Cardiol Date: 2011-07-20 Impact factor: 4.164
Authors: Catherine D Krawczeski; Stuart L Goldstein; Jessica G Woo; Yu Wang; Nuntawan Piyaphanee; Qing Ma; Michael Bennett; Prasad Devarajan Journal: J Am Coll Cardiol Date: 2011-11-22 Impact factor: 24.094
Authors: Anja Haase-Fielitz; Peter R Mertens; Michael Plass; Hermann Kuppe; Roland Hetzer; Mark Westerman; Vaughn Ostland; John R Prowle; Rinaldo Bellomo; Michael Haase Journal: Crit Care Date: 2011-08-04 Impact factor: 9.097
Authors: Junichi Ishigami; Yuhree Kim; Yingying Sang; Steven P Menez; Morgan E Grams; Hicham Skali; Amil M Shah; Ron C Hoogeveen; Elizabeth Selvin; Scott D Solomon; Christie M Ballantyne; Josef Coresh; Kunihiro Matsushita Journal: Clin Chem Date: 2021-01-08 Impact factor: 8.327
Authors: Jef Van den Eynde; Art Schuermans; Jan Y Verbakel; Marc Gewillig; Shelby Kutty; Karel Allegaert; Djalila Mekahli Journal: Eur J Pediatr Date: 2022-01-17 Impact factor: 3.183
Authors: Jason H Greenberg; Michael Zappitelli; Yaqi Jia; Heather R Thiessen-Philbrook; Christina A de Fontnouvelle; F Perry Wilson; Steven Coca; Prasad Devarajan; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2018-02-22 Impact factor: 10.121
Authors: Aiping Zhang; Kitipong Uaesoontrachoon; Conner Shaughnessy; Jharna R Das; Sree Rayavarapu; Kristy J Brown; Patricio E Ray; Kanneboyina Nagaraju; John N van den Anker; Eric P Hoffman; Yetrib Hathout Journal: Toxicol Rep Date: 2015
Authors: Allison Meisner; Kathleen F Kerr; Heather Thiessen-Philbrook; Francis Perry Wilson; Amit X Garg; Michael G Shlipak; Peter Kavsak; Richard P Whitlock; Steven G Coca; Chirag R Parikh Journal: Biomark Res Date: 2018-01-12